RxDoctor Payments Data

Hoa Tran, MD

Family Medicine · Lubobck, TXNPI 1386841203

Payments from drug & device makers

$9,243in general payments, 2019–2025

Across 532 payments — averaging $17.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$1K
  • Novo Nordisk$761
  • Otsuka America Pharmaceutical, Inc.$450
  • Amgen$448
  • Lundbeck LLC$447
  • plus $4K from 46 others

What the payments were for

  • Food & beverage$9,13299%
  • Education$1111%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,243 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$159,216
Medicare patients
437
Services billed
2,714

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide142$160,539
OzempicSemaglutide65$62,182
JanuviaSitagliptin Phosphate39$32,570
EliquisApixaban22$21,675
LinzessLinaclotide26$14,371
JardianceEmpagliflozin11$13,109
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$12,813
FarxigaDapagliflozin Propanediol13$12,196
Combivent RespimatIpratropium/Albuterol Sulfate12$5,643
Albuterol Sulfate HfaAlbuterol Sulfate229$5,288
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$3,248
Levothyroxine Sodium332$3,209
Gabapentin144$2,202
LantusInsulin Glargine,hum.Rec.Anlog13$1,860
SynthroidLevothyroxine Sodium23$1,839

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$1,016$160,539142 claims
Novo NordiskOzempic$761$62,18265 claims
PfizerEliquis$334$21,67522 claims
Boehringer IngelheimJardiance, Combivent Respimat$18$18,75323 claims
AbbVieLinzess, Synthroid$1,730$16,21149 claims
GSKTrelegy Ellipta$55$12,81317 claims
AstraZenecaFarxiga$297$12,19613 claims
Sanofi-aventis U.S. LLCLantus$96$1,86013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Lubobck

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →